2015 in review: FDA approval of new drugs.
The myriad new molecular entities (NMEs) approved by the US Food and Drug Administration (FDA) in 2015 reflected both the opportunities and risks associated with the development of new medicines. On the one hand, the approval of 45 NMEs was among the highest ever recorded. Likewise, the diversity underlying the mechanistic basis of new medicines suggests continued broadening relative to the predominate trends of the past few decades. On the other hand, closer inspection indicates that business model decisions surrounding orphan indications and consolidation could be placing the industry in an ever-more precarious position, with severe implications for the sustainability of the entire enterprise.
Center for Research Innovation in Biotechnology, Washington University in St. Louis, St. Louis, MO, USA. Electronic address: michael.kinch@wustl.edu.
Michael S
MS
Kinch
D017277:Drug Approval; D009965:Orphan Drug Production; D014481:United States; D014486:United States Food and Drug Administration